2026-10-30 11:00:22 UTC#544907newforecastnews
RXRX stock news
RXRX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-27 11:00:45 UTC#520826newconfirmednews
Upstart Holdings (UPST) Q3 2026 earnings preview: analysts expect $365.18M revenue and $0.21 EPS
2026-10-21 13:00:00 UTC#493244newconfirmednews
Upstart Holdings expands partnership with MIT Federal Credit Union to include indirect auto lending
2026-10-20 21:57:49 UTC#489615newconfirmednews
Upstart Holdings secures $200 million senior secured revolving credit facility to support bank establishment
2026-10-19 11:05:56 UTC#479875newconfirmednews
ARK Investment Management adds to CoreWeave, Meta, and Recursion; trims Personalis and Toast
seeking alphaimportance 0.30trust 0.70ARK Investment Management LLC 0CoreWeave, Inc. +0.30Meta Platforms, Inc. +0.30+2 entities
2026-10-19 10:34:30 UTC#479665newconfirmednews
Needham reiterates Buy rating on Recursion Pharmaceuticals with $8 price target
tradingviewimportance 0.40trust 0.60Needham & Company, LLC +0.20Recursion Pharmaceuticals, Inc. +0.40REC-4881 +0.40+2 entities
2026-10-16 07:20:00 UTC#470426newconfirmednews
Recursion Pharmaceuticals, Inc. average analyst price target raised to $7.32, consensus remains Buy
2026-10-16 07:00:00 UTC#470377updateconfirmednews
Recursion Pharmaceuticals reports positive REC-4881 Phase 1b/2 clinical data, extends cash runway into 2029
tradingviewimportance 0.60trust 0.70Recursion Pharmaceuticals, Inc. +0.60REC-4881 +0.60Sanofi S.A. +0.40+1 entities
2026-10-15 13:03:55 UTC#465922duplicateconfirmednews
Recursion Pharmaceuticals reports $200M equity offering and Sanofi partnership milestone
2026-10-15 13:00:29 UTC#465895newconfirmedpress release
Recursion Pharmaceuticals and Sanofi advance first-in-class immunology candidate to development pipeline
2026-10-15 12:53:00 UTC#465838newconfirmednews
Recursion Pharmaceuticals prices 61.54M share offering at $3.25 per share to raise $200 million
tradingviewimportance 0.60trust 0.80Recursion Pharmaceuticals, Inc. -0.40Leerink Partners LLC 0Goldman Sachs Group, Inc. 0+2 entities
2026-10-15 12:52:46 UTC#465892duplicateconfirmedpress release
Recursion Pharmaceuticals prices $200 million offering of 61.54 million shares at $3.25 per share
2026-10-15 06:00:00 UTC#463570newconfirmednews
Kinnevik AB Q3 2026 NAV rises 1% to SEK 29.8B, YTD NAV down 17%
2026-10-13 11:52:00 UTC#451894newconfirmednews
Goldman Sachs cuts Upstart Holdings price target to $28.00 from $39.00
2026-10-07 13:00:00 UTC#425817newconfirmednews
Upstart Holdings partners with Credit Union of Denver to expand personal loan marketplace
2026-10-05 12:13:13 UTC#413245newconfirmeddata release
Upstart September loan originations reach $1.38B, a 2.7% increase month-over-month
2026-10-05 11:45:00 UTC#413068newconfirmeddata release
Upstart Holdings (UPST) reports October UMI of 1.49, down slightly from 1.50 in September
2026-09-23 13:00:00 UTC#355567newconfirmednews
Upstart expands Commonwealth Credit Union partnership to include HELOC and indirect auto lending
2026-09-22 10:17:00 UTC#347805newconfirmednews
BTIG maintains $43 price target on Upstart Holdings (UPST)
2026-09-21 13:24:59 UTC#342782newconfirmednews